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therapeutics (D'souza et al., 2015) , as well as tissue engineering and regenerative medicine (Richardson et al., 2010) . In addition to their natural healing and regenerative potentials, genetic modification of hMSCs could allow for targeted tissue tropism and delivery of recombinant factors in hMSC therapies.
Genetic modification by viral transduction is efficient, but suffers from safety issues related to immunogenicity and insertional mutagenesis (Nayerossadat, Maedeh, & Ali, 2012) , as well as small transgene capacity and difficult design and scale-up (Yin et al., 2014) .
Nonviral methods that overcome many of the shortcomings of viral delivery suffer from low efficiency, especially in hMSCs. For example, optimized transfection of hMSCs with the commercially available Lipofectamine 2000 (Invitrogen, Carlsbad, CA) results in only 10-30% of cells successfully transfected (Hoare et al., 2010; Madeira et al., 2010; Peng, Gao, Xue, Huang, & Zhuo, 2013; Ribeiro et al., 2010) , and the ubiquitously used 25 kDa branched polyethylenimine is only able to achieve about 20% transfection (Ahn et al., 2008; Peng et al., 2013; W. Wang et al., 2011) . Furthermore, both lipid-and polymer-based transfection reagents are associated with significant toxicity in hMSCs (Corsi, Chellat, Yahia, & Fernandes, 2003; King, Kouris, Choi, Ogle, & Murphy, 2012) . The low efficiency and high toxicity of nonviral gene delivery limits the translation of genetically modified hMSCs to clinical applications. Therefore, more efficient and less toxic nonviral gene delivery methods to hMSCs are needed to advance their potential clinical applications. To improve nonviral gene delivery, our group has focused on elucidating the biology of transfection to develop new strategies for improved efficiency.
Our previous work has sought to improve and better understand the biology of nonviral gene delivery by pharmacologically 'priming' cells for increased transgene expression (Nguyen, Beyersdorf, Riethoven, & Pannier, 2016) through modulation of relevant molecular pathways that are important to the biological processes involved in gene delivery (Martin, Plautz, & Pannier, 2015a; Martin, Plautz, & Pannier, 2015b) . Specifically, we investigated anti-inflammatory glucocorticoid (Gc) drugs as priming candidates in hMSCs due to reports in other cell types that Gc can increase transfection efficiency by increasing plasmid DNA (pDNA) nuclear internalization or reducing the inflammatory response to transfection (Braun et al., 1999; Kim, Kim, Bae, Choi, & Lee, 2009 ). In hMSCs, derived from bone marrow stromal cells (BMSCs) of multiple donors, we showed that 90 to 360 nM dexamethasone (DEX), a Gc drug, delivered 0-30 min before delivery of pDNA lipoplexes increased the transgenic luciferase activity about 10-fold, increased transgenic enhanced green fluorescent protein (EGFP) mean fluorescence intensity of transfected cells about two-fold, increased transfection efficiency about three-fold (i.e., percent of EGFP + transfected cells), increased duration of transgene expression, and ameliorated transfection-induced metabolic decline, all while retaining differentiation capacity (Kelly, Plautz, Zempleni, & Pannier, 2016) . Others have reported similar enhancement of transfection using steroids in other cell types. For example, priming of various cell types with steroids (i.e. glucocorticoids, estrogens, and progesterone) has generally shown moderate increases in gene delivery to a wide variety of cell types (i.e., 2-4-fold transgene expression increases; Bernasconi et al., 1997; Braun et al., 1999; Chen, Shank, Davis, & Ziady, 2011; Choi & Lee, 2005; Jain, Seth, & Gewirtz, 1999; Koster et al., 2002; Köster et al., 2006; Lin et al., 2003; Nair, Rodgers, & Schwarz, 2002) , with a few exceptions (i.e., 10-fold increase in myoblasts; Braun et al., 1999) and 900-fold increase in bronchial epithelial cells (Wiseman, Goddard, & Colledge, 2001 ).
This work investigates, for the first time, the molecular mechanisms of transfection with and without DEX-priming in hMSCs derived from multiple donors of both BMSCs and adipose tissue derived (AMSCs).
Since DEX-priming of hMSC transfection is mediated by binding of the glucocorticoid receptor (GR; Kelly et al., 2016) , which makes use of similar intracellular transport mechanisms as transfected pDNA does (Davies, Ning, & Sánchez, 2002; Dhanoya, Wang, Keshavarz-Moore, Fassati, & Chain, 2013; Echeverria et al., 2009; Galigniana, Harrell, O'Hagen, Ljungman, & Pratt, 2004; Harrell et al., 2004; Lachish-Zalait et al., 2009) , and GR modulates gene expression related to antiinflammatory and stress pathways (Ratman et al., 2013) , we analyze nonviral gene delivery barriers and pathways in hMSCs including internalization, cytoplasmic transport, nuclear translocation, transgene transcription, translation, and cellular stress response, along with the effects of DEX-priming on each of these barriers and pathways. We also explore the effects of different pDNA regulatory sequences on transgene expression and DEX-priming. Studying transfection, pharmacological priming, and the molecular mechanisms involved provides key insights into the gene delivery process to aid in the rational design of new gene delivery technologies and simple priming strategies for hMSCs and other clinically relevant cell types.
| MATERIALS AND METHODS

| Cell culture
Bone marrow derived hMSCs (BMSCs) were purchased at passage 2 from Lonza (Walkersville, MD) or acquired at passage 1 from the Texas A&M Institute for Regenerative Medicine Health Science Center College of Medicine (Bryan, TX). All BMSCs were positive for CD29, CD44, CD105, and CD166 cell surface markers and negative for CD14, CD34, and CD45. Adipose derived hMSCs (AMSCs) were purchased at passage 1 from Lonza and were positive for CD13, CD29, CD44, CD73, CD90, CD105, CD166, and negative for CD14, CD31, CD45 cell surface markers. All human cells were acquired with informed consent using established ethical methods approved by appropriate authorities. All experiments and methods were performed in accordance with relevant guidelines and regulations. All experimental protocols were approved by the University of Nebraska-Lincoln Institutional Biosafety Committee. See Supporting Information Table S1 for BMSC and AMSC donor information. All cells were expanded and cultured in minimum essential medium ⍺ (MEM⍺; Gibco, Grand Island, NY) supplemented with 10% heatinactivated fetal bovine serum (Gibco), 6 mM L-glutamine (Gibco), and 1% penicillin-streptomycin (10,000 U/ml; Gibco) and incubated at 37°C with 5% CO 2 . At 80% confluence cell media was removed and cells were washed with 1× phosphate-buffered saline (PBS) and dissociated with 0.25% trypsin-ethylenediaminetetraacetic acid (EDTA; Gibco), then an equal volume of growth medium was added and cells were pelleted to remove trypsin-EDTA, resuspended, and counted with trypan blue staining and a hemocytometer before diluting in growth medium (for transfection studies as described next) or medium with 5% dimethyl sulfoxide (DMSO) to 6 × 10 4 cells/ ml for freezing in 1 ml aliquots stored in liquid nitrogen.
For transfection experiments, after dissociation and counting as described above, hMSCs were seeded into 48 or 96 well plates (Corning Life Sciences, Corning, NY) or T25 flasks (Corning), at passages 3 through 5, at 6,000 cells/cm 2 and allowed to adhere until about 80% confluence, then transfected as described below. buffer solution (10 mM Tris, 1 mM EDTA; pH 7.4) at −20°C.
| Priming reagents
Lipoplexes were formed with Lipofectamine LTX (LF-LTX) or
Lipofectamine 3000 (LF-3000; Invitrogen) in serum free Opti-MEM media (Invitrogen) following the manufacturer's instructions and as noted in the text. Amount of DNA and DNA:lipid ratios were optimized to allow for high transfection and low toxicity. All transfections were performed with 0.2 µg pDNA/cm 2 of cell growth area and DNA:lipid ratio of 1:2 complexed with LF-3000 following the manufacture's protocol. In inhibitor studies, BMSCs were transfected identically as above, but with LF-LTX. 
| Transfection assessment
| Plasmid internalization studies
To quantify plasmid internalization into cells and nuclei, hMSCs were seeded into T-25 flasks in triplicate, then DEX-primed and transfected with 5.26 µg pEGFP-Luc complexed with LF-3000 as described above. 
| Transgene mRNA quantification studies
To quantify relative mRNA transcript copy numbers, 48 hr after BMSC and AMSC transfection with LF-3000 as described above, cells were lysed and fractionated with TRIzol reagent (Invitrogen, Carlsbad, CA) following the manufacturer's protocol. Aqueous RNA was purified using a RNeasy micro kit (Qiagen, Hilden, Germany).
RNA was treated with DNAse I (Thermo Fisher Scientific) and reverse-transcribed using iScript cDNA kit (Bio-Rad, Hercules, CA).
qRT-PCR for relative EGFP mRNA transcript copy number was performed as described above and calculated by ΔΔC t method normalizing to endogenous control RPL13A. See Supporting Information Table S2 for primer sequences (IDT). Comparative analyses were made between conditions using one-way analysis of variance (ANOVA) with Tukey's posttest.
| Total protein synthesis assay
| Statistical analysis
All experiments were performed in triplicate (n = 3) on duplicate days. Certain donors were used for certain experiments, such that at least two donors were tested for each experiment. Given limited availability of cells, it was not possible to test all donors in all experiments. All values are reported as mean ± standard error of the mean. Comparative analyses were completed using one-way ANOVA with Tukey's posttest or unpaired t test. Statistical difference was considered at p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***). Statistics and fold changes highlighted within figures are between treated versus control groups. All statistics were evaluated using Prism
GraphPad software (GraphPad Software, Inc., La Jolla, CA).
3 | RESULTS
| DEX-priming increases both transgenic luciferase expression and activity in hMSCs
BMSCs and AMSCs derived from multiple human donors (denoted as Donors number or D#; Supporting Information Table S1 ) were F I G U R E 1 Dexamethasone (DEX)-priming significantly increases hMSC transgenic luciferase amount and further increases transgenic luciferase activity. hMSCs were primed with 150 nM DEX 25 min before transfection with Lipofectamine-3000 plasmid DNA complexes, and lysed for analysis after 48 hr. DEX-treated hMSCs displayed about 10-fold increases in the luciferase activity, normalized to total cellular protein, over ethanol (EtOH) treated cells in (a) Donor 4 (D4) BMSCs and (b) D1 AMSCs. In contrast, DEX only increased transgenic luciferase amount by about two-fold relative to EtOH, as quantified by western blot analysis, in transfected (c) D5 BMSCs, and (d) D1 AMSCs. Luciferase activity data plotted as mean ± SEM (n = 3) of luciferase luminescence relative light units per mg of total protein (RLU/mg protein). Relative luciferase amount data from western blot is normalized to total protein and plotted as mean ± SEM (n = 2). Asterisks (*) denote significance to EtOH conditions (*p ≤ 0.05; ***p ≤ 0.001). Fold change increase over EtOH conditions shown in parentheses. AMSCs: adipose tissue derived from mesenchymal stem cells; BMSCs: bone marrow derived from mesenchymal stem cells; hMSCs: human mesenchymal stem cells; SEM: standard error of mean
| Cytoplasmic transport inhibition moderately decreases enhancement by DEX
Since both pDNA and the glucocorticoid receptor (GR), the receptor bound by DEX and other Gcs to induce their effects by genomic and nongenomic mechanisms (Strehl et al., 2011) , are known to utilize similar cytoplasmic transport mechanisms (i.e., dynein motor protein on microtubules; Davies et al., 2002; Dhanoya et al., 2013; Echeverria et al., 2009; Galigniana et al., 2004; Harrell et al., 2004; Lachish-Zalait et al., 2009 ) and GR binding is required for DEX-mediated transfection enhancement in hMSCs (Kelly et al., 2016) One-way ANOVA was performed, as comparisons were made between a control condition and conditions in which one independent variable was manipulated (i.e. inhibitor vs. no inhibitor, whereas not varying whether or not DEX was present). Appropriate controls were treated with ethanol in lieu of inhibitor or DEX. AMSC: adipose tissue derived from mesenchymal stem cells; BMSC: bone marrow derived from mesenchymal stem cells; hMSCs: human mesenchymal stem cells; SEM: standard error of mean
| Enhancement by DEX is pDNA sequence element independent
Given that the above studies may not fully explain the large DEXmediated enhancement of hMSC transgene expression, we next explored the importance of specific pDNA sequence elements on hMSC transfection and priming by DEX. hMSCs were DEX-primed and transfected with various modifications of pEGFP-Luc plasmid (Supporting Information Figure S1 ) complexed with LF-3000. Plasmids To simplify interpretation of results, we only tested the effect of SV40
and GRE sequences within pDNA constructs with a CMV promoter,
given that all other experiments in this paper and in our previous work used CMV promoter (Kelly et al., 2016) . Replacing the CMV promoter with the mammalian EF1⍺ or the rous sarcoma virus promoter (RSV)
resulted in large decreases in transgenic luciferase activity in the absence of DEX (i.e., 90-95% less transgenic luciferase activity than unmodified pEGFP-Luc [CMV]) in D2 and D4 BMSCs, and D2 AMSC (Figure 5a-c) . In contrast, DEX-priming resulted in similar relative foldchange luciferase activity enhancement compared to EtOH VC (i.e., about 6-10-fold), regardless of any plasmid sequence modifications tested in D2 and D4 BMSCs, and D2 AMSCs (Figure 5a-c) . DEX even induced an increase of about 40-fold compared to EtOH VC in D4
BMSCs when transfected with RSV plasmid (Figure 5b ). In summary, One-way analysis of variance was performed, as comparisons were made between a control condition and conditions in which one independent variable was manipulated (i.e., inhibitor vs. no inhibitor, whereas not varying whether or not DEX was present). Appropriate controls were treated with ethanol in lieu of inhibitor or DEX. AMSCs: adipose tissue derived from mesenchymal stem cells; BMSCs: bone marrow derived from mesenchymal stem cells; SEM: standard error of mean pDNA regulatory sequences can have dramatic effects on transgene expression in hMSCs, but no sequence modifications tested reduce enhancement induced by DEX. 
| DEX does not increase transgene mRNA levels
| DISCUSSION
This work explored the mechanisms of hMSC nonviral transfection and DEX-induced enhancement of transgene expression. This DEXpriming effect on transfection is robust and consistent as evidenced by large increases in transgenic luciferase activity levels relative to hMSCs transfected in the absence of the DEX (i.e., about 10-fold luciferase activity; Figure 1a,b) ; the effect is seen in both BMSCs and AMSCs derived from multiple human donors. While DEX and other steroids have been used to increase nonviral gene delivery efficiency in several cell types before this study, other cell types generally show only moderate transgene expression increases (i.e. 2-4-fold increases relative to VC; Bernasconi et al., 1997; Braun et al., 1999; Chen et al., 2011; Choi & Lee, 2005; Jain et al., 1999; Koster et al., 2002; Köster et al., 2006; Lin et al., 2003; Nair et al., 2002) compared to those seen here in hMSCs. Although DEX increased transgenic luciferase activity normalized to total protein by about 10-fold in transfected hMSCs, DEX only increased the amount of transgenic luciferase protein by about two-fold, as quantified by western blot analysis normalized to total protein (Figure 1c,d) , suggesting that DEX-priming somehow increases transgenic enzyme activity downstream of transgenic protein synthesis. Our results showing increased transgenic enzyme activity in addition to increased transgenic protein production (all relative to VCs) are probably not specific to only luciferase transgenes because we previously reported DEX-priming yielded 4-7-fold increases in transgenic β-galactosidase enzyme activity, whereas also increasing transgenic EGFP mean fluorescence intensity by about two-fold, all relative to VC (Kelly et al., 2016) . It is likely that hMSC transfection could be primed with many other Gc drugs in addition to DEX, as our previous work demonstrated that priming with cortisol similarly resulted in significant enhancement of transgene expression in transfected hMSCs (Kelly et al., 2016) . In addition to replicating our previous reports of DEX-priming transfection in BMSCs derived from multiple human donors (Kelly et al., 2016) , here we also extend our simple protocol to demonstrate similar enhancement in AMSCs from multiple human donors. (Kelly et al., 2016) . Since DEX has been shown to alter nuclear membrane permeability (Kastrup, Oberleithner, Ludwig, Schafer, & Shahin, 2006; Shahin, 2006; Shahin et al., 2005) , and the GR has been shown to interact with similar transport and nuclear import pathways as pDNA, we quantified the number of plasmid copies in transfected hMSCs and isolated nuclei, with and without DEX-priming. DEX-priming did not increase cellular or nuclear internalization of pDNA, but actually resulted in slightly less internalized plasmid copies per cell and nuclei 48 hr after transfection (Figure 2) , possibly due to increased proliferation of DEX-treated hMSCs diluting pDNA number within dividing cells, as we previously showed DEX ameliorates the decrease in hMSC viability brought on by transfection toxicity, as quantified by WST-1 proliferation assays (Kelly et al., 2016) . It should be noted that these pDNA internalization results are not consistent with our previous data where we showed increased plasmid internalization induced by DEX in hMSCs (Kelly et al., 2016) , but those previous experiments were performed with only one biological replicate (n = 1), used cells from different human donors than used in the current work, and also used the LF-LTX transfection reagent and iodoxanol gradient nuclear isolation methods. In contrast, the LF-3000 transfection reagent, which was used in this current study due to its improved transfection in AMSCs over LF-LTX, as well as sucrose gradient nuclear isolation methods were used in this current study. Thus, the different results reported here can be attributed to changes in donors and nuclear isolation methods, but also the results reported greatly improve the statistical power, given the use of hMSCs from four human donors. Furthermore, these differing results may indicate that the mechanism of enhancement could be specific to different transfection reagents.
Since both pDNA and the GR are known to utilize similar cytoplasmic transport mechanisms involving microtubules and dynein (Davies et al., 2002; Dhanoya et al., 2013; Echeverria et al., 2009; Galigniana et al., 2004; Harrell et al., 2004; Lachish-Zalait et al., 2009; Vaughan, DeGiulio, & Dean, 2006) Previous studies in other cell types have shown lipofection is enhanced by treatment with inhibitors of microtubule-based transport by preventing transport of complexes to lysosomes (Cardarelli et al., 2016; Hasegawa, Hirashima, & Nakanishi, 2001; Lindberg et al., 2001; L. Wang & MacDonald, 2004) , but our studies used significantly lower Noco concentration due to its toxicity in hMSCs.
However, even using a lower concentration, Noco treatments did reduce fold-change enhancement of transgene expression mediated by DEX-priming, suggesting transport was inhibited to attenuate DEX-mediated priming of transfection. pDNA transport to nuclei on microtubules has been shown to involve pDNA binding of transcription factors (Badding, Vaughan & Dean, 2012) , so others have suggested activated GR can directly transport pDNA via dynein on microtubules through the cytoplasm to nuclei, resulting in increased nuclear pDNA and thus increased transfection (Chen et al., 2011) .
However, it appears this is not the mechanism by which DEX increases transgene expression in hMSCS, since DEX did not increase pDNA nuclear internalization (Figure 2) . Furthermore, while inhibiting cytoplasmic transport reduced the fold-change increase in transgene expression by DEX, it is likely that inhibition of the transport of GR or other factors on microtubules resulted in downstream effects that modulate nonviral gene delivery success as opposed to modulating pDNA transport. To better understand these results, we next explored the role of nuclear import pathways.
In addition to cytoplasmic transport, pDNA and GR also employ similar mechanisms in their nuclear translocation in that they both interact with importins and the nuclear pore complex during internalization (Dhanoya et al., 2013; Echeverria et al., 2009; Lachish-Zalait et al., 2009) . Since pDNA nuclear translocation has been shown to be a limiting barrier to transfection success in other cell types (Ludtke, Sebestyén, & Wolff, 2002; Young, Benoit, & Dean, 2003) , we aimed to study transfection and DEX-priming of hMSC transfection in response to inhibition of classical nuclear import mechanisms (Figure 4 ). Large transgenic luciferase activity decreases by IM treatment in the absence of DEX reiterates the importance of the importin β-mediated nuclear import pathway to successful transfection, which has been reported in other cell types (Badding, Lapek, Friedman, & Dean, 2013) , and confirms its importance in hMSCs. However, observing no decrease in DEX-mediated foldchange enhancement by nuclear import inhibitors (Figure 4) , along with our data showing DEX does not increase pDNA nuclear internalization (Figure 2 ), suggests that mechanisms by which DEXpriming enhances transfection are independent of nuclear import pathways.
After demonstrating that inhibition of cytoplasmic transport pathways significantly decreased transfection enhancement mediated by DEX-priming (Figure 3) , and that inhibition of importin β-mediated nuclear import in absence of DEX dramatically decreased hMSC transgenic luciferase activity (Figure 4) , we next explored how specific pDNA sequences, known to modulate transport, nuclear localization, and transcription, affect hMSC transfection and DEXpriming by modifying the plasmid pEGFP-Luc (Supporting Information Figure S1 ) used in all previous experiments. The SV40 enhancer, found in unmodified pEGFP-Luc, is a known DNA targeting sequence (DTS; Badding, Vaughan & Dean, 2012; Breuzard et al., 2008; Cramer et al., 2012; D. A. Dean, Strong, & Zimmer, 2005; D. Dean, 1997; Gonçalves et al., 2009; Miller & Dean, 2009; Van Gaal et al., 2011; Wilson, Dean, Wang, & Dean, 1999; Young et al., 2003) , which is bound by several transcription factors that can increase transport and nuclear internalization of pDNA in some cell types (Badding et al., 2013) . Removal of the SV40 DTS inhibited hMSC transfection in the absence of DEX as expected, but priming by DEX seems to be independent of mechanisms related to DTS binding, as there was no significant difference in fold-change enhancement by DEX relative to DEX fold-change enhancement of transgene expression from unmodified pEGFP-Luc (Figure 5 ), suggesting again that DEX does not increase transfection by modulating pDNA intracellular transport. Another sequence element of interest is consensus GREs, welldefined short palindromic repeats found within Gc-induced genes' promoters, which are bound by GR dimers to recruit transcriptional machinery (i.e. transactivation; Ratman et al., 2013) . In addition to promoting transcription from constructs containing GRE sequences (Dames, Laner, Maucksch, Aneja & Rudolph, 2007; Mader & White, 1993) DEX has also been shown to induce GRdependent transcriptional activation of transgenes driven by CMV promoter in some cell types (Inoue-Toyoda, Kato, Nagata, & Yoshikawa, 2015; Van Damme et al., 2015) . Replacing the CMV promoter with the mammalian EF1⍺ or the rous sarcoma virus promoter (RSV) resulted in dramatic decreases in absolute transgenic luciferase activity in the absence of DEX, but large and significant fold-change enhancement by DEX-priming was still demonstrated ( Figure 5 ). This result distinguishes the DEX-priming effect in hMSCs from previous reports of sequence-dependent direct activation of CMV promoter by Gc. Our experiments conducted with modified plasmids indicate that hMSC transfection enhancement by DEXpriming is independent of plasmid sequence elements and indicates that the priming effect may not be mediated by direct association of pDNA with the GR to promote transcription. These results also show that modifications to plasmid sequence like the removal of the SV40 enhancer can significantly affect transgene expression levels in unprimed and DEX-primed hMSCs, similar to reports that demonstrate the addition of the SV40 enhancer increases nuclear internalization of pDNA by about 10-fold and more than doubles plasmid average rate of movement in A459 cells relative to pDNA lacking the SV40 enhancer (Badding et al., 2013) . Furthermore, our results reiterate the importance of promoter choice in hMSCs, as replacing the strong CMV promoter with the endogenous mammalian EF1α promoter or viral RSV promoter dramatically reduced transgenic luciferase activity in the absence of DEX. To our knowledge, this is the first comparison of promoter performance in hMSCs, but studies of transgene expression in rats MSCs have shown the EF1α promoter to outperform a CMV promoter (Ferreira et al., 2012; McGinley et al., 2011; Qin et al., 2010) , suggesting hMSC physiology differs significantly from MSCs obtained from other species.
Our results reported here show DEX-priming does not modulate pDNA internalization, intracellular transport, or nuclear import mechanisms, but the increase in hMSC transfection may be the result of other downstream mechanisms, so we next sought to determine if DEX increases hMSC transgene expression at the transcriptional level. However, DEX did not significantly increase the amount of transgene mRNA present in hMSCs 48 hr after transfection with pDNA ( Figure 6 ). This result suggests that DEX-priming does not increase transgene transcription rate or mRNA stability, but may enhance transgene expression at the posttranscriptional level.
We next aimed to explore pathways related to transfection and DEXpriming of transfection that could modulate posttranscriptional mechanisms of transgene expression.
Since nonviral gene delivery has been shown to induce cellular stresses (Martin et al., 2015a; Martin, Plautz, & Pannier, 2013) , like reactive oxygen species, proinflammatory factors, and apoptotic mediators (Lonez, Vandenbranden, & Ruysschaert, 2012) , and it is well known that many cellular stresses result in inhibited protein synthesis, we tested the effect of transfection and DEX-priming on hMSC total cellular protein synthesis. hMSC total protein synthesis was significantly decreased by transfection, but was significantly rescued by DEX-priming (Figure 7 ), which may be partly responsible for increased transgenic protein production (Figure 1 ). Since it is well known that protein synthesis is inhibited during apoptosis (Jeffrey, Bushell, Tilleray, Morley, & Clemens, 2002) and we have previously shown that DEX rescues transfection-induced hMSC viability decreases, we next demonstrated, by annexin staining, that transfection induces hMSC apoptosis and that DEX-priming significantly reduces this apoptotic response (Figure 8 ), which presumably allows for the increased translation of transgenic protein found in DEXprimed hMSCs (Figure 1a,b) . Our results are consistent with reports that DEX treatment ameliorates transfection-induced hMSC viability decrease as measured by WST-1 cell proliferation assay (Kelly et al., 2016) . Furthermore, DEX has also been shown to rescue cytotoxicity and apoptosis induced in transfected HC92 rat cardiomyocytes (Kim et al., 2009) , and reduced death of chinese hamster ovary (CHO) cells producing recombinant protein by modulating apoptosis-related gene expression (Jing et al., 2012) . In addition to increasing transgenic protein synthesis, attenuation of apoptosis by DEX-priming could also promote the observed increase in relative transgenic enzyme HAMANN ET AL.
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activity by modulating posttranslational events like folding or activesite stabilization, as Gc has been shown to improve CHO recombinant protein production by reducing protein aggregation through upregulation of genes that modulate redox conditions (Qian, Jing, & Li, 2010) . DEX has also been shown to modulate endoplasmic reticulum (ER) stress responses by promoting correct protein folding (Das et al., 2013) , trafficking (Fujii et al., 2006) , and by preventing apoptosis (Mihailidou, Panagiotou, Kiaris, Kassi, & Moutsatsou, 2016) . Further study of posttranslational mechanisms like transgenic protein folding as well as the effect of transfection and DEX-priming on inflammatory and stress pathways, like oxidative and ER stress, are needed to elucidate details that may be key to understanding unprimed and DEX-primed nonviral gene delivery to hMSCs. In addition to future mechanistic studies, we will also apply our DEXpriming protocol to express therapeutic transgenes in hMSCs, as safe and efficient nonviral delivery of therapeutic genes to hMSCs is needed to translate to clinical applications.
| CONCLUSIONS
In summary, these studies systematically investigated the mechanisms of hMSC nonivral transfection and DEX-priming of transfection.
DEX-priming of hMSCs presents a simple protocol to significantly enhance nonviral gene delivery success in therapeutically relevant cells, and results in increased production of transgenic protein, as well as increased transgenic enzyme activity. We show that hMSC transgene expression is largely affected by pDNA promoter and enhancer sequence changes, but DEX-mediated enhancement is unaffected by any pDNA sequence changes. DEX-mediated enhancement is not the result of increased pDNA cellular or nuclear internalization, or transgene mRNA transcription or stability. Our studies demonstrate that DEX-priming inhibits hMSC apoptosis induced by transfection to prevent subsequent protein synthesis inhibition, which allows increased translation of transgenic protein.
Our findings highlight the importance of understanding downstream molecular biological mechanisms of nonviral gene delivery like translational and posttranslational events that limit transfection success. Further exploration of these pathways will be key in the rational design of new technologies to advance the many clinical applications of safe and efficient genetic modification of hMSCs and other therapeutically relevant primary cells.
